Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

NCT02432404•University of Washington

Summary

To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1 week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR use among women either with BV or at high risk for BV. The investigators will also recruit women who are HSV2-infected.

Eligibility

Age

18 - 40 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•≥18-40 year old women
•BV+ by Amsel criteria and Nugent score OR history of BV in the prior 6 months
•Willing to use the NuvaRing as directed
•Not intending or wishing to become pregnant over the course of the study
•Capable of providing written informed consent

Exclusion Criteria

•Current pregnancy
•Desire/intent to become pregnant over the course of the study
•Women who are less than 6 weeks postpartum
•Contraindications to hormonal contraceptive use per package insert, including history of deep vein thrombosis, smoking in women older than 35 years
•Current IUD
•Unable to comprehend consent material because of language barrier or psychological difficulty

Locations (1)

UW Virology Research Clinic

Seattle, Washington, United States

Key Dates

Start Date

March 1, 2016

Primary Completion Date

November 1, 2021

Completion Date

November 1, 2021

Last Updated

February 5, 2025

Enrollment

ACTUAL participants

Conditions

Bacterial Vaginosis

Interventions

NuvaRing

DRUG

An Open Single-armed Investigation to Evaluate the Safety of pHyph Following a Prolonged Treatment Duration in Adult Women With Bacterial Vaginosis

NCT07394777

Bacterial Vaginosis (BV)

View study

ENROLLING_BY_INVITATION

Vaginal Ecosystem and Network in the United States Study

NCT06472765

Bacterial VaginosisCandidiasis+9 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

Inclusion Criteria

Exclusion Criteria

An Open Single-armed Investigation to Evaluate the Safety of pHyph Following a Prolonged Treatment Duration in Adult Women With Bacterial Vaginosis

Vaginal Ecosystem and Network in the United States Study

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

Feasibility of an Oral Intervention for Sexual Health in Transgender Men

A Randomised, Partly-blinded Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Bacterial Vaginosis Compared With an Untreated Control Group

Real-world Performance and Safety of Cerviron® in the Treatment of Vaginitis